Reporting from ELCC 2019 in Geneva, J. Wolf comments on the importance of searching for actionable genetic aberrations in NSCLC. He elaborates upon different gene fusions and in particular TRK fusion in terms of identifying patients who could benefit from effective new targeted therapies.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.